NCT02801578View on ClinicalTrials.gov

A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 6, 2016

Primary Completion Date

January 28, 2019

Study Completion Date

January 28, 2019

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Ibrutinib

Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT02801578 - A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter